Focal Radiotherapy for Previously Treated Prostate Cancer Patients

Launched by ROYAL NORTH SHORE HOSPITAL · Mar 2, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of radiation treatment called focal stereotactic radiation therapy (SBRT) for men with locally recurrent prostate cancer. The goal is to see if this treatment is safe and effective for patients who have already received radiation therapy in the past. Specifically, it aims to help those whose cancer has come back but is still contained to a small area of the prostate.

To be eligible for this trial, participants need to be men aged 65 to 74 who have had their initial radiation treatment more than four years ago and have experienced a specific type of cancer recurrence. They must also have a life expectancy of at least ten years and a prostate-specific antigen (PSA) level below 10. Participants can expect to receive focused radiation aimed precisely at the area where the cancer has returned, and will be monitored closely for any side effects. If you're interested in this trial, it’s important to discuss it with your doctor to see if it might be a good fit for you.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men \> 4yrs from external beam radiotherapy (EBRT) meeting the Phoenix definition of biochemical failure or men \> 5yrs from EBRT if neo-adjuvant and/or adjuvant androgen deprivation therapy (ADT) also used
• • Recurrence localised to less than 1 lobe of prostate on both PMSA and multi-parametric MRI (less than equal to cT2a)
• • Recurrence must be biopsy proven, with positive biopsies limited to the PET and MRI suspicious region.
• • Life expectancy at least 10yrs from time of SBRT
• • PSA \< 10
• Exclusion Criteria:
• • Recurrence in immediate proximity to rectum (unless able to have hydrogel)
• • Grade 3 or more toxicity from previous EBRT
• • Contra-indicated for fiducial insertion
• • GS 8,9 or 10 disease previously (relative - consider if decent disease free interval)